Technology | 2009.08.26
Dyax Announces Developments in Licensing and Funded Research Program
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ:DYAX) announced today successful advancement into Phase 1 clinical trials of two candidates identified using Dyax’s proprietary phage display technology by licensees of the Company’s Licensing and Funded Research Program (LFRP). LFRP licensee ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, recently announced it initiated clinical development for oncology candidate IMC-EB10, ImClone’s anti-FLT3 antibody,
For more information, please visit
http://www.businesswire.com/news/home/20090826005166/en
